SEO URLwww.firestrike.ai/deals/catalent-novo-nordisk-acquisition-2026
acquisitionAnnounced · Mar 9, 2026PharmaceuticalsSource · SpeculativeArticle · Factual
Novo Nordisk acquires Catalent
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
—
Target
Catalent
NYSE: CTLT · Bridgewater, New Jersey
Acquirer
Novo Nordisk
Full Acquisition
Status
Completed
Novo Nordisk agreed to acquire Catalent. Reported deal value: Undisclosed. Status: Completed. Sector: Pharmaceuticals. Target headquarters context: Bridgewater, New Jersey, United States.
This page summarizes publicly available information about the transaction as of 2026-03-09. Figures and status may change as filings and press coverage update.
The FDA has rejected Incyte supplemental application to add non-small cell lung cancer to the label of its anti-PD-1 antibody Zynyz, citing manufacturing issues at Novo Nordisk Catalent - acquired site
Deal timeline
Announced
Mar 9, 2026 · biospace.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals. Figures and status may change as sources update.
Sources: biospace.com · Primary article · FireStrike proprietary index